Ultrasound imaging company Terason said today that it has inked a deal with y DiA Imaging Analysis to provide DiA Imaging’s cardiac solutions on Terason’s point-of-care ultrasound devices.
The partnership fills a market need for more accurate and objective image analysis for clinicians in hospitals and outpatient settings, that commonly analyze ultrasound images visually, according to Burlington, Mass.-based Terason.
DiA’s LVivo Toolbox uses pattern recognition, machine learning and deep learning-based technology to identify cardiac functions and abnormalities and generate results that may reduce the subjectivity associated with cardiac ultrasound analysis.
“Left ventricle analysis represents the most frequent indication for an echo study and is pivotal for patient evaluation, management, and as an indicator for treatment initiation,” said Terason CEO Alice Chiang in a news release. “We always strive to offer users the most innovative solutions. By joining with DiA, we will empower users with our best-in-class devices together with DiA’s most powerful automated algorithms, that provide superior solutions for managing patients with heart failure or cardiovascular disease.”
“DiA and Terason have many shared values, and I am pleased that we have joined forces,” said Hila Goldman-Aslan, CEO of Be’er Sheva, Israel-based DiA Imaging. “The point-of-care ultrasound market is evolving quickly, and AI is driving this market. Partnering with Terason is another step toward accomplishing DiA’s vision to make ultrasound analysis smarter and accessible to all.”
DiA inked a multi-year, non-exclusive licensing and professional services deal with GE Healthcare (NYSE:GE) in 2017.
